IP Library › Patent Application 12194686
Patent Application
App. No. 12/194,686

USE OF EIF-5A1 SIRNA TO PROTECT ISLETS CELLS FROM APOPTOSIS AND TO PRESERVE THEIR FUNCTIONALITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/194,686
Abstract

The present invention relates to methods for improving the viability, recovery and functionality of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability and functionality of islets.

Claims (7)

1 . A method for preserving the functionality of harvested islet cells after isolation comprising administering eIF-5A1 siRNA to the islet cells of an islet cell donor prior to islet isolation, wherein the eIF-5A1 siRNA inhibits expression of eIF-5A1 in the islet cells and thereby inhibits apoptosis in the islet cells and preserves the functionality of the harvested islet cells.

2 . The method of claim 1 wherein the eIF-5A1 siRNA targets the following nucleotide sequence of eIF-5A1: 5′-AAAGGAATGACTTCCAGCTGA-3′ (SEQ ID NO: 1); 5′-AAGATCGTCGAGATGTCTACT-3′ (SEQ ID NO: 2); 5′-AAGGTCCATCTGGTTGGTATT-3′ (SEQ ID NO: 3); or 5′-AAGCTGGACTCCTCCTACACA-3′ (SEQ ID NO: 4).

3 . The method of claim 1 wherein the eIF-5A1 siRNA comprises the nucleotide sequence 5′-AAAGGAAUGACUUCCAGCTGAdTdT-3′ (SEQ ID NO: 5).

4 . The method of claim 1 wherein the siRNA is administered via intraperotoneal injection to the islet cell donor.

5 . A method for inhibiting islet cells from undergoing apoptosis during a donor harvesting process comprising administering eIF-5A1 siRNA to an islet cell donor via intraperotoneal injection to islet cell donor prior to islet isolation, wherein the eIF-5A1 siRNA inhibits expression of eIF-5A1 in the islet cells and thereby inhibits apoptosis in the islet cells.

6 . The method of claim 5 wherein the eIF-5A1 siRNA targets the following nucleotide sequence of eIF-5A1: 5′-AAAGGAATGACTTCCAGCTGA-3′ (SEQ ID NO: 1); 5′-AAGATCGTCGAGATGTCTACT-3′ (SEQ ID NO: 2); 5′-AAGGTCCATCTGGTTGGTATT-3′ (SEQ ID NO: 3); or 5′-AAGCTGGACTCCTCCTACACA-3′ (SEQ ID NO: 4).

7 . The method of claim 5 wherein the eIF-5A1 siRNA comprises the nucleotide sequence 5′-AAAGGAAUGACUUCCAGCTGAdTdT-3′ (SEQ ID NO: 5).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2008
From: THOMPSON, JOHN E.; DINARELLO, CHARLES A.
To: SENESCO TECHNOLOGIES, INC.
Reel/Frame 021978/0979 →